دورية أكاديمية
أعرض في EDS

Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study

التفاصيل البيبلوغرافية
العنوان: Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study
المؤلفون: Keigo Koda, Yasunori Enomoto, Yoichiro Aoshima, Yusuke Amano, Shinpei Kato, Hirotsugu Hasegawa, Takashi Matsui, Koshi Yokomura, Eisuke Mochizuki, Shun Matsuura, Naoki Koshimizu, Meiko Morita, Suguru Kojima, Ayano Watanabe, Yoshiyuki Oyama, Masaki Ikeda, Hideki Kusagaya, Tomohiro Uto, Jun Sato, Shiro Imokawa, Masato Kono, Dai Hashimoto, Yosuke Kamiya, Mikio Toyoshima, Kazuhiro Asada, Masako Morita, Masashi Mikamo, Hideki Yasui, Hironao Hozumi, Masato Karayama, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, Takafumi Suda
المصدر: Therapeutic Advances in Chronic Disease, Vol 13 (2022)
بيانات النشر: SAGE Publishing, 2022.
سنة النشر: 2022
المجموعة: LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950
الوصف: Introduction: Although recent advances in chemotherapy for lung cancer are remarkable, most clinical trials have excluded patients with interstitial lung disease (ILD) due to the concern of developing acute exacerbation (AE) of ILD. Hence, accumulating original evidence of cancer treatment for this population is important. Methods: Between 2016 and 2020, a prospective observational study was conducted across 11 Japanese hospitals. Patients with chemotherapy- naïve , inoperable, advanced lung cancer with ILD were included. The primary outcome was the frequency of AE-ILD after registration; the secondary outcomes were the risk factor of AE-ILD and the efficacy of chemotherapy. Results: Among 124 patients enrolled, 109 patients who received chemotherapy were analyzed. The median age was 72 years, and the majority showed usual interstitial pneumonia (UIP)/probable UIP pattern upon chest computed tomography. The median percent-predicted forced vital capacity (%FVC) was 81% (interquartile range: 66–95%). After registration, 23 patients (21.1%; 95% confidence interval [CI]: 14.4–29.7%) developed AE-ILD. The logistic analysis revealed that lower %FVC slightly but significantly increased the risk of AE-ILD (odds ratio per 10% decrease: 1.27; 95% CI: > 1.00–1.62). Overall response rates/median overall survival times in non-small-cell lung cancer and small-cell lung cancer for the first-line chemotherapy were 41% (95% CI: 31–53)/8.9 months (95% CI: 7.6–11.8) and 91% (95% CI: 76–98)/12.2 months (95% CI: 9.2–14.5), respectively. Conclusion: AE-ILD during chemotherapy is a frequent complication among patients with lung cancer with ILD, particularly those with lower %FVC. Conversely, even in this population, passable treatment response can be expected.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2040-6231
20406223
Relation: https://doaj.org/toc/2040-6231
DOI: 10.1177/20406223221108395
URL الوصول: https://doaj.org/article/4e2ad180958d45ad92e06a35b7c35380
رقم الأكسشن: edsdoj.4e2ad180958d45ad92e06a35b7c35380
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20406231
20406223
DOI:10.1177/20406223221108395